Amarin Corp plc Files 8-K on Financials
Ticker: AMRN · Form: 8-K · Filed: Oct 29, 2025 · CIK: 897448
| Field | Detail |
|---|---|
| Company | Amarin Corp PLC\UK (AMRN) |
| Form Type | 8-K |
| Filed Date | Oct 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-K
Related Tickers: AMRN
TL;DR
AMRN filed an 8-K on Oct 29, 2025, covering financial results and exhibits.
AI Summary
Amarin Corporation plc filed an 8-K on October 29, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The filing details the company's status as a UK-based entity incorporated in England and Wales, with its principal executive offices located in Dublin, Ireland.
Why It Matters
This 8-K filing provides investors with crucial updates on Amarin's financial performance and condition, impacting their investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Amarin Corporation plc (company) — Registrant
- October 29, 2025 (date) — Date of Report
- England and Wales (jurisdiction) — State of incorporation
- Dublin 2 (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Amarin Corporation plc?
The primary purpose is to report on Amarin Corporation plc's results of operations and financial condition, along with financial statements and exhibits.
On what date was this 8-K report filed?
The report was filed on October 29, 2025.
Where is Amarin Corporation plc incorporated?
Amarin Corporation plc is incorporated in England and Wales.
What is the address of Amarin Corporation plc's principal executive offices?
The principal executive offices are located at 8th Floor, One Central Plaza, Dame Street, Dublin 2.
What is the SIC code for Amarin Corporation plc?
The Standard Industrial Classification (SIC) code for Amarin Corporation plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 550 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-10-29 07:05:27
Filing Documents
- amrn-20251029.htm (8-K) — 56KB
- amrn-ex99_1.htm (EX-99.1) — 481KB
- img114078973_0.jpg (GRAPHIC) — 26KB
- 0001193125-25-254620.txt ( ) — 714KB
- amrn-20251029.xsd (EX-101.SCH) — 32KB
- amrn-20251029_htm.xml (XML) — 5KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On October 29, 2025, Amarin Corporation plc (" Amarin ") issued a press release announcing its financial results for the three and nine months ended September 30, 2025 and 2024 (the " Press Release "). A copy of the Press Release is furnished herewith as Exhibit 99.1. The information in this report furnished pursuant to Item 2.02 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended (the "Securities Act"), if such subsequent filing specifically references the information furnished pursuant to Item 2.02 of this report.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release (results of operations), dated October 29, 2025 (furnished herewith) 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) * * *
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 29, 2025 Amarin Corporation plc By: /s/ Aaron Berg Aaron Berg President and Chief Executive Officer